Pharmaceutical Business review

Labopharm’s pain drug gets approval in South Korea and Australia

The company expects its product to be launched in South Korea and Australia later this year.

James Howard-Tripp, president and CEO, Labopharm, said: “South Korea and Australia are important components of the global commercialization plan for our product. We are now working with our marketing partners in both countries towards the launches of our product later in 2008.”